Table 2.
Demographics and clinical characteristics2. a Mean, b Mean since symptom onset, cMedian based on manual segmentation.
| MS (n = 30) | |
|---|---|
| Demographics | |
| Subject type (RRMS/SPMS/PPMS) | 22/2/6 |
| Male, n (%) | 10 (33 %) |
| Agea, y (range) | 44.4 ± 11.7 (21.7–61.9) |
| Disease durationb, y (range) | 7.4 ± 6.4 (0.7–23.8) |
| Clinical characteristics | |
| EDSSa (range) | 3.3 ± 1.9 (0–6.5) |
| Lesionc volume, ml (range) | 5.9 (1.7–51.2) |
| Disease-modifying treatment | |
| (none/TEC/GIL/COP/TYS/OCR/AUB) | 81/1/3/1/9/1 |
| Non-disease modifying drug | |
| (FAM) | 6 |
2
TEC=dimethyl fumarate (Tecifidera); GIL=fingolimod (Gilenya); COP=glatiramer acetate (Copaxone); TYS=Natalizumab (Tysabri); OCR=Ocrelizumab (Ocrevus); AUB=Teriflunomide (Aubagio); FAM=fampridine (Fampyra).